2012 best year, 2010 worst year forDSM

For years it are very positive times for the investors in DSM. Even without dividend payments the stock is one of the outperformers from as well chemical sector as the Dutch exchange. The received dividends are a cherry on the cake for investors.

The matrix above shows DSM's historical returns expressed in the different entry years in the left axis.

The year 2010 was the worst year for the stock, as it declined by a whopping 16 percent. So far, 2008 is the best year for the company, as the stock gained 88 percent. The investor who invested in the stock in 2008 (price at that time 18,33 euros) now even has a price gain of 109 percent now.

For this year DSM's revenue will be around 9,26 billion euros. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 8,63 billion euros.

Historical revenues and results DSM plus estimates 2018

financial analysis

The analysts expect for 2018 a net profit of 1,02 billion euros. Most of the analysts anticipate on a profit per share of 5,85 euros. Based on this the price/earnings-ratio is 12,33.

Huge dividend DSM

For this year the analysts expect a dividend of 2,19 euros per share. DSM's dividend yield thus equals 3,04 percent. The average dividend yield of the chemical companies equals a low 1 percent.

Most recent target prices around 102 euros

The most recent recommendations for the chemical company are from Kepler Capital Markets, Macquarie Research and Barclays.

DSM's market capitalization is around 12,62 billion euros. The DSM stock was the past 12 months quite volatile. Since last January the stock is 10 percent lower. This year the stock price moved between 68 and 93 euro. Since 2008 the stock price is almost 257 percent higher.

Historical stock prices DSM

financial analysis dsm

On Friday the stock closed at 72,12 euros.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.